Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

26.39 +0.08 (+0.30%)
Streaming Delayed Price Updated: 2:10 PM EDT, Sep 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Exelixis Inc

< Previous 1 2 3 4 5 Next >
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
From Exelixis, Inc.
Via Business Wire
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
From Exelixis, Inc.
Via Business Wire
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
From Exelixis, Inc.
Via Business Wire
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
From Exelixis, Inc.
Via Business Wire
Exelixis Elects Jacqueline Wright to Its Board of Directors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis to Release Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
From Exelixis, Inc.
Via Business Wire
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes
From Exelixis, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.